INTRODUCTION
============

Chronic obstructive pulmonary disease (COPD) remains a frequent disease associated with significant economic burden. In the European Union, the total direct costs of respiratory disease are estimated to be about 6% of the total health care budget, with COPD accounting for more than a half of this cost (38,6 billion Euros) \[[@R1]\].

In order to guide therapy, the patients with stable COPD are assessed and classified in 4 groups (A, B, C, and D) by combined COPD assessment. This assessment considers separately following aspects of the disease: current level of patient's symptoms, severity of the spirometric abnormality, exacerbation risk, and presence of comorbidities. The most comprehensive questionnaires used in routine practice for assessment of the symptoms and the patient's health status are COPD Assessment Test (CAT) and COPD Control Questionnaire (CCQ) \[[@R2]\]. CAT is an 8-items unidimensional questionnaire of health status impairment in COPD patients. It was developed to be applicable worldwide, validated translations are available in many languages, and its usefulness is documented in several studies \[[@R3]\].

The course of COPD can be affected by acute events characterized by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medications, known as exacerbations \[[@R2]\]. COPD exacerbations have serious negative impact on patient quality of life, lung function, and socioeconomic costs so their prevention, early detection, and prompt treatment have a great importance in the management of the disease. Despite treatment with maintenance medications, COPD patients continue to have exacerbations, so new medications and disease management interventions are warranted to reduce the severity and frequency of exacerbations and the related cost impact of the disease \[[@R4]\].

Respiratory infections account for up to 80% of exacerbations, of which bacterial infections are involved in around 50-70% \[[@R5]\]. The criteria of Anthonisen (i.e. increase in baseline dyspnea, cough, and/or sputum production) \[[@R6]\] are still the most important classification system to identify patients likely to be infected with bacterial pathogens based on presentation of clinical symptoms \[[@R7],[@R8]\]. According to the actual version of the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) \[[@R2]\], antibiotics should be given to patients with type I exacerbation (presence of all three symptoms), with type II exacerbation (presence of two symptoms if increased purulence of sputum is one of them), as well as in patients who require mechanical ventilation (invasive or noninvasive). Depending on the severity of an exacerbation and/or the severity of the underlying disease, an exacerbation can be managed in an outpatient or inpatient setting. More than 80% of exacerbations can be ambulatory treated with bronchodilators, antibiotics and corticosteroids \[[@R9]\]. Severe COPD exacerbations are managed in the hospital, potential indications for hospital assessment or admission are given in the actual GOLD version \[[@R2]\]. Research studies have shown that it may take several weeks for patients to recover from a single moderate-severe exacerbation and some patients may never recover fully \[[@R10]\].

The aim of the present study is to evaluate the course of CAT scores during bacterial exacerbations of COPD treated in outpatient setting.

MATERIALS AND METHODOLOGY
=========================

Study Design
------------

An observational, prospective study was performed at the Institute for Occupational Health of R. Macedonia, Skopje - WHO Collaborating Center and GA^2^LEN Collaborating Center in the period November 2013-May 2014. The CAT scores of COPD patients with bacterial exacerbation treated in outpatient setting at initial visit were compared with the CAT scores of the same patients 10 and 30 days after initial visit.

Study Population
----------------

Patients of both genders, aged 43 to 74 years, were recruited in the study if they met the following inclusion criteria: patients with COPD demonstrated by spirometry performed in stable state with a post-bronchodilator forced expiratory volume in one second/force vital capacity (FEV1/FVC) ratio \< 0.7; smokers or ex-smokers of at least 10 pack-years smoked; patients with bacterial exacerbation defined according the Anthonisen criteria \[[@R6]\] and treated in outpatient setting according to the actual recommendations \[[@R2]\].

The exclusion criteria in the study were: patients with another respiratory disease (e.g. bronchial asthma, bronchiectasis, pneumonia, cystic fibrosis, etc.); bacterial exacerbations requiring hospital treatment; and patients who did not retain sufficient capacity for normal conduction of the study.

All participants were informed about the study and their written consent was obtained.

Completion of the CAT
---------------------

All patients with bacterial exacerbation completed the CAT at initial visit (i.e. at the time of diagnosis of exacerbation and beginning of its treatment), 10 days after initial visit (i.e. at the time when treatment was ended) and 30 days after the initial visit.

The questionnaire consisted 8 original CAT items \[[@R11]\] translated in Macedonian:

Q1 *I never cough/I cough all the time*

Q2 *I have no phlegm (mucus) in my chest at all/My chest is completely full of phlegm (mucus)*

Q3 *My chest does not feel tight at all/My chest feel very tight*

Q4 *When I walk up a hill or one flight of stairs I am not breathless/When I walk up a hill or one flight of stairs I am very breathless*

Q5 *I am not limited doing activities at home/I am very limited doing activities at home*

Q6 *I am confident leaving my home despite my lung condition/I am not at all confident leaving my home because of my lung condition*

Q7 *I sleep soundly/I don't sleep soundly because of my lung condition*

Q8 *I have lots of energy/I have no energy at all*

Each question had score ranging from 0 to 5 points (0 = no impairment). The patients had to circle the appropriate point for each question at the time of exacerbation and at the time when the exacerbation was resolved (i.e. 4 to 6 weeks from the initial visit). An overall CAT score was derived as a sum of the scores for each response. It may range from 0 to 40 providing a measure of the impact of the disease on a patient's health status, i.e. of the impact of an exacerbation and recovery from an exacerbation on a patient's health status. The overall CAT scores more than 30 and more than 20 indicate very high and high impact of COPD on patient's health status, respectively. The overall CAT score ranging from 10 to 20 indicates medium impact, the overall CAT score less than 10 indicates low impact of the disease on the patient's health status, whereas the overall CAT score of 5 represents the upper limit of normal in healthy non-smokers \[[@R11]\].

Statistical Analysis
--------------------

The quantitative variables were expressed as mean values with standard deviation (SD), whereas the qualitative variables as absolute frequencies and percentages. A comparison of the mean scores of the particular CAT questions, as well as the mean overall CAT scores was done by Student's t-test. A *P*-value less than 0.05 was considered as statistically significant. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 11.0 for Windows.

RESULTS
=======

From a total of 102 patients enrolled in the study 9 were lost to follow-up, 7 were excluded due to insufficient information for analysis and 5 were hospitalized in the first two or three days due to worsening of exacerbation, leaving 81 eligible participants.

The demographic and clinical characteristics of the study population are given in Table **[1](#T1){ref-type="table"}**.

The mean scores for each CAT question at initial visit varied from 2.6 for *Q7* to 3.5 for *Q1*, whereas the mean scores for each CAT question 10 days after initial visit varied from 1.7 for *Q6* to 2.6 for *Q1*. Statistically significant reduction in the mean scores 10 days after initial visit as compared to the mean scores at initial visit was registered for all eight questions (Fig. **[1](#F1){ref-type="fig"}**).

We registered reduction of mean overall CAT score 10 days after initial visit as compared to its score at initial visit of 6.9 ± 2.7 points (16.8 *vs* 23.7; *P* \< 0.001) (Fig. **[2](#F2){ref-type="fig"}**).

The mean scores for each CAT question 30 days after initial visit varied from 1.3 for *Q6* to 2.4 for *Q1*. Statistically significant reduction in the mean scores 30 days after initial visit as compared to the mean scores 10 days after initial visit was registered for all eight questions (Fig. **[3](#F3){ref-type="fig"}**).

We registered reduction of mean overall CAT score 30 days after initial visit as compared to its score 10 days after initial visit of 2.9 ± 1.2 points (13.9 *vs* 16.8; *P* \< 0.005). The mean overall CAT score 30 days after initial visit was reduced for 9.8 ± 4.5 points as compared to its value at initial visit (13.9 *vs* 23.7; *P* \< 0.001) (Fig. **[4](#F4){ref-type="fig"}**).

DISCUSSION
==========

As in the past COPD was considered as a disease characterized by breathlessness, a simple measure of breathlessness, such as the Modified British Medical Council (mMRC) Questionnaire was used for symptoms assessment. In the last years it has been recognized that COPD has multiple systematic effects requiring more comprehensive symptom assessment instead of measure of breathlessness \[[@R12]\]. In addition, several studies have indicated that the relationship between values of the lung function parameters (FEV~1~) and health status in patients with COPD generally is not strong \[[@R12],[@R13]\]. As recognized by the GOLD strategic document, the health status, lung function and exacerbations frequency are complementary and all together define the severity of the COPD in a particular patient \[[@R2]\].

By time, it was considered that the most comprehensive questionnaires for assessment of health status in the patients with COPD, e.g. the St. George Respiratory Questionnaire (SGRQ) \[[@R14]\], are too complex for use in routine practice, so there was a need for developing of shorter questionnaires for multidimensional assessment of COPD which can be used in everyday work. The CAT and the CCQ \[[@R15]\] are short and easy-to-use in routine practice questionnaires developed in the last decade.

The CAT is a simple-to-complete tool which can measure the impact of COPD on the patient's health in order to manage optimally and to reduce the burden of the disease as much as possible. The development of the CAT has involved established methodologies used to develop psychometric tools \[[@R15]\]. It has been validated in prospective studies and their results have indicated that it can be used globally \[[@R16],[@R17]\].

So far, the usefulness of the CAT in assessment of the impact of COPD exacerbations on health status, as well as of the responding to the treatment and degree of recovery are evaluated in the process of the test validation \[[@R18],[@R19]\] and in a few studies \[[@R20]-[@R23]\]. Results from the assessment done in the process of validation indicate that a difference or change in the overall CAT score of 2 or more suggests a clinically significant difference or change in health status (Minimum Clinically Important Difference -- MCID) \[[@R18]\]. On the other side, based on their own results, Tsiglianni *et al*. \[[@R20]\] estimated the CAT's MCID at 3,76 points. Results from the first validation study suggest that CAT scores in patients with moderate-severe exacerbations are approximately 5 units higher than in those who have stable COPD \[[@R16]\]. In this study patients who responded to the treatment for their exacerbation reduced their CAT score by 2 units in 14 days, whereas patients who did not respond to the treatment had no change in the score \[[@R19]\]. In addition, according to the results of the study performed by Mackay *et al*. \[[@R21]\], the CAT score has to improve by at least 5 units to consider that the patient has recovered from exacerbation.

In the present study we evaluated changes in the CAT scores in COPD patients with bacterial exacerbation diagnosed and treated in outpatient setting according to the actual recommendations. The CAT was completed by the same patients at initial visit (i.e. at the time when the exacerbation was diagnosed and the treatment began); 10 days after initial visit following the actual GOLD recommendations for the length of antibiotic therapy of 5 to 10 days \[[@R2]\], and 30 days after initial visit taking into account that recovery from exacerbation should last several weeks and some patients may never recover fully \[[@R2],[@R10]\].

The mean overall score at initial visit has value indicating high impact of COPD on patient's health status. The highest particular mean scores were registered for cough, phlegm and breathlessness at low level of physical effort that was expected as these symptom are considered as major symptoms of COPD exacerbation \[[@R2],[@R6]\]. We registered significant reduction of the mean scores of all eight CAT questions at the end of antibiotic therapy (i.e. 10 days after initial visit), that resulted in significant reduction of mean overall CAT score of 6.9 points. At the last visit (30 days after initial visit) we registered additional reduction of the mean scores of all eight questions and significant reduction of the mean overall CAT score of 2.9 points as compared to its value registered at the second visit. The reduction of the mean overall CAT score at the third visit as compared to its value at the first visit was 9.8 points.

Similar results were obtained in the multicentric study performed in Spain by Miravitlles *et al*. \[[@R23]\] aimed at assessment of the course of CAT and CCQ scores during recovery from exacerbations of COPD including 164 outpatients and 322 inpatients. In this study, at the time of exacerbation, the mean overall CAT score of the study participants was 22.0 (22.8 in inpatients and 20.4 in outpatients). After recovery, i.e. 4 to 6 weeks from initial visit, the authors found significant reduction of 9.9 points (8.9 in inpatients and 10.4 in outpatients).

The findings of this study are subjects of at least three limitations. Firstly, relatively small number of the study participants from one center could have certain implications on the data obtained and its interpretation. Secondly, we had no CAT scores of the same patients before the exacerbation occurred, so we could not compared them with CAT scores at the time of exacerbation and 30 days after its diagnosis and treatment. Currently, there is no well-established MCID for CAT, so the degree of impairment and recovery in our patients could not be compared with its acceptable value. The strength of the study is its observational design in a sample of outpatients with bacterial exacerbation of COPD evaluated in three time points of the course of the exacerbation.

CONCLUSION
==========

In conclusion, in an observational, prospective study aimed at assessment of the course of CAT scores during bacterial exacerbations of COPD treated in outpatient setting, we found significant improvement in the patient's health status during recovery from exacerbation as compared to their health status at the time of exacerbation. Our findings confirm the CAT as a useful tool for the measurement of the health status during the exacerbation and for evaluation of recovery. In addition, there is a need of new studies in order to establish the role of the CAT in the managing of COPD exacerbations.

Declared none.

ETHICAL APPROVAL
================

The Ethical Committee of the Institute of Occupational Health of R. Macedonia, Skopje -- WHO Collaborating Center and GA^2^LEN Collaborating Center gave approval for performing the study and publishing the results obtained (03-273/06.2014).

AUTHORS PARTICIPATIONS
======================

JM participated in the study design, data collection, managing the analyses of the study, and writing all versions of the manuscript. JKB participated in the study design, managing the analyses of the study, as well as writing all versions of the manuscript. KV performed the statistical analysis and participated in the managing of the analyses of the study. SS and DM participated in the data collection and in the managing of the analyses of the study. All authors read and approved the final manuscript.

CONFLICT OF INTEREST
====================

The authors confirm that this article content has no conflict of interest.

![Mean scores of the CAT questions at initial visit and 10 days after initial visit.](TORMJ-9-39_F1){#F1}

![Mean overall CAT scores at initial visit and 10 days after initial visit.](TORMJ-9-39_F2){#F2}

![Mean scores of the CAT questions at initial visit, 10 and 30 days after initial visit.](TORMJ-9-39_F3){#F3}

![Mean overall CAT scores at initial visit, 10 and 30 days after initial visit.](TORMJ-9-39_F4){#F4}

###### 

Demographic and clinical characteristics of the study population.

  --------------------------------------------------------------------------------
  Variable                                                       Study Subjects\
                                                                 (n = 81)
  -------------------------------------------------------------- -----------------
  Males\                                                         57 (70.4)\
  Mean age (years)                                               56.1 ± 10.7

  Active smokers\                                                37 (45.7)\
  Ex-smokers\                                                    44 (54.3)\
  Mean pack-years smoked\                                        18.6 ± 5.7\
  Exposed to ETS Mean BMI\                                       28 (34.6)\
  Mean duration of\                                              25.4 ± 2.9\
  diagnosed COPD (years)\                                        7.3 ± 3.1\
  Mean FEV1 at initial visit (% pred)\                           60.3 ± 7.8\
  Mean FEV1 30 days after beginning of the treatment (% pred)\   64.2 ± 6.2\
  Exacerbation in previous year Comorbidities\                   1.8 ± 0.7\
  Arterial hypertension\                                           22 (27.2)\
  Diabetes type 2\                                               14 (17.3)\
  Ischemic heart disease                                         10 (12.3)
  --------------------------------------------------------------------------------

Data are presented as n, mean ± SD, or n (%).

BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; % pred: % of predicted value; SD: standard deviation.
